ImmuneWalk Therapeutics - Seed Round
$7M Raised
Let’s talk about what happens when inflammation meets its match, and it doesn’t even see it coming.
ImmuneWalk Therapeutics just walked off with $7M in fresh seed capital, and if you're sleeping on this one, consider this your wake-up shot of espresso, extra bold. Founded in 2023 by biotech heavyweight Professor Dror Harats, yeah, the same Dror who steered VBL Therapeutics (Nasdaq:VBLT) onto Nasdaq and pulled in $300M+ from Wall Street’s suits, ImmuneWalk isn’t just playing in the inflammation sandbox. They're pouring concrete under it and building the damn lab.
Headquartered in Pearl River, NY (with an R&D outpost in Petach Tikvah, Israel), this squad is coming for immune inflammatory diseases with surgical precision. Their secret sauce? Monocyte Targeting Technology, MTT for those in the know. Sounds like a fighter jet. Acts like one, too. While most therapies out there take the shotgun approach, suppress everything and hope for the best, ImmuneWalk’s MTT is the sniper on the ridge. It locks onto MOSPD2, a key adhesion checkpoint protein on monocytes and neutrophils, and shuts down their migration into inflamed tissues. Translation: less damage, more control, no blood cell wipeout. Target acquired. Threat neutralized.
Their first big gun is IW-601, a monoclonal antibody that’s already cleared the Single Ascending Dose phase in humans and left a trail of compelling data in preclinical models of multiple sclerosis, rheumatoid arthritis, IBD, and NASH. Proof-of-concept? Delivered. Safety? Confirmed. Momentum? Untouchable. They’re presenting clinical data at EULAR - European Alliance of Associations for Rheumatology 2025 on June 11 and then heading to BIO International Convention in Boston to make sure the industry hears the drumbeat loud and clear. The next readout, Multiple Ascending Dose, is landing in Q4. Set your calendars for October. Big moves inbound.
Let’s call this what it is, a clinical-stage assassin that’s stayed under the radar long enough. $20M+ had already been sunk into the program before this seed round even happened. Add the $7M from an institutional investor and the management team, and you’ve got a company that's not guessing its way forward. They’re executing with clarity, capital, and a clinical plan that doesn’t flinch.
Salute to Dr. Harats and the core crew, Sam Backenroth, Tami Rachmilewitz, and Oshrat Propheta meiran. You didn’t just secure a seed round, you just put the inflammatory disease market on notice. And if you're watching from the sidelines? Don't blink.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.